Home:
Meeting
Highlights: Clinical
Trials
Appendix
A1. Phase I Pilot Study of HER2/neu Intracellular
Domain Protein Pulsed Autologous Dendritic Cells in Patients with
HER2/neu Expressing Advanced Malignancies Showing No Evidence of
Disease After Standard Treatment
Protocol
IDs: DUMC-1528-99-9, NCI-G00-1800
Michael A.
Morse, Principal Investigator
Ph: 919-681-3480 Duke Comprehensive Cancer Center
Durham, North Carolina
A2.
Phase I Pilot Study of p53 (264-272) Peptide Vaccine and Tumor Specific
Mutant p53 Peptide Vaccine in HLA-A2 Patients with Stage IV, Recurrent,
or Progressive Adenocarcinoma of the Breast
Protocol
IDs: NCI-99-C-0138, NCI-T99-0075, NCI-NMOB-9902
Samir N.
Khleif, Principal Investigator
Ph: 301-496-0901 Medicine Branch Bethesda, Maryland
A3.
Phase I Pilot Study of Sequential High Dose Cisplatin/ Cyclophosphamide/Etoposide
and Ifosfamide/Carboplatin/Paclitaxel with Autologous Stem Cell
Support for Advanced Carcinomas
Protocol
IDs: CHNMC-IRB-94098 , NCI-V96-1042
George Somlo,
Principal Investigator
Ph: 626-359-8111 Beckman Research Institute, City of Hope Los Angeles,
California
A4.
Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients
with Refractory Metastatic Cancer Expressing MAGE-12 Antigen
Protocol
IDs: NCI-00-C-0182, NCI-1034
Francesco
M. Marincola, Principal Investigator
Ph: 301-496-3098 Surgery Branch Bethesda, Maryland
A5.
Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen
(CEA) RNA-Pulsed Autologous Human Cultured Dendritic Cells in Patients
with Metastatic Malignancies Expressing CEA
Protocol IDs: NCI-G97-1272, DUMC-1817-99-10R3, DUMC-96098
Herbert Kim
Lyerly, Principal Investigator
Ph: 919-681-8350 Duke Comprehensive Cancer Center Durham, North
Carolina
A6.
Phase I Study of Allogeneic Peripheral Blood Stem Cell Transplantation
in Patients With Metastatic or Unresectable Small Cell Lung Cancer,
Breast Cancer, Testicular Germ Cell Cancer, Melanoma, or Renal Cell
Cancer
Protocol
IDs: NU-99H2, NCI-G00-1838
Steven T.
Rosen, Principal Investigator
Ph: 312-908-5250 Robert H. Lurie Comprehensive Cancer Center, Northwestern
University Chicago, Illinois
A7.
Phase I Study of CD80-Modified Allogeneic Breast Cancer Cell Line
to Vaccinate HLA-A2 Positive Women with Breast Cancer
Protocol IDs: PPMC-IRB-94-78, NCI-V98-1379 , OCC-ONC-9408-L
John W. Smith,
II, Principal Investigator
Ph: 503-232-7000 Earle A. Chiles Research Institute at Providence
Portland Medical Center Portland, Oregon
A8.
Phase I Study of High Dose Paclitaxel, Cyclophosphamide, and Thiotepa
Followed By Autologous Peripheral Blood Stem Cell Rescue and Radiotherapy
in Patients with Advanced Breast Cancer
Protocol
IDs: NU-96B1, NCI-G99-1641
Jane N. Winter,
Principal Investigator
Ph: 312-695-6180 Robert H. Lurie Comprehensive Cancer Center, Northwestern
University Chicago, Illinois
A9.
Phase I Study of Interleukin-12 and Trastuzumab (Herceptin) in Patients
with HER2-Neu Overexpressing Malignancies
Protocol
IDs: OSU-99H0185, NCI-T99-0032
Charles L.
Shapiro, Principal Investigator
Ph: 614-293-7530 Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio
A10.
Phase I Study of Intraperitoneal Aminocamptothecin Colloidal Dispersion
in Patients with Cancer Predominantly Confined to the Peritoneal
Cavity
Protocol
IDs: NYU-9753, NCI-T97-0123
Franco M.
Muggia, Principal Investigator
Ph: 212-263-6485 NYU School of Medicine's Kaplan Comprehensive Cancer
Center New York, New York
vA11.
Phase I Study of Irinotecan and Gemcitabine in Patients with Unresectable
or Metastatic Solid Tumors
Protocol
IDs: NU-98X3, NCI-G99-1588, P-UPJOHN-976475157
Al Bowen
Benson, III, Principal Investigator
Ph: 312-695-6180 Robert H. Lurie Comprehensive Cancer Center, Northwestern
University Chicago, Illinois
A12.
Phase I Study of LMB-9 Immunotoxin in Patients with Advanced Colon,
Breast, Non-Small Cell Lung, Bladder, Pancreas, or Ovarian Cancer
Protocol
IDs: MSGCC-9981, NCI-511, MSGCC-IRB-0200123
Petr F. Hausner,
Principal Investigator
Ph: 410-328-2565 Marlene & Stewart Greenebaum Cancer Center,
University of Maryland Baltimore, Maryland
A13.
Phase I Study of LMB-9 Immunotoxin in Patients with Advanced Solid
Tumors That Express Lewis Y Antigen
Protocol
IDs: NCI-98-C-0078A, NCI-T98-0005, NCI-MB-400
Robert Kreitman,
Principal Investigator
Ph: 301-496-6947 Medicine Branch Bethesda, Maryland
A14.
Phase I Study of Mutant MGMT Gene Transfer into Human Hematopoietic
Progenitors to Protect Hematopoiesis During O6-Benzyguanine and
Carmustine Therapy of Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Protocol
IDs: CWRU-2Y97, NCI-T97-0060
Stanton L.
Gerson, Chair
Ph: 216-368-1176 Ireland Cancer Center
A15.
Phase I Study of Neoadjuvant Capecitabine, Cyclophosphamide, and
Epirubicin in Women with Locally Advanced or Inflammatory or Large
Operable Breast Cancer
Protocol
IDs: IDBBC-10991-CEX
Herve Bonnefoi,
Principal Investigator
Ph: 011-41-22-382-33-11 Hopital Cantonal Universitaire de Geneva
Geneva, Switzerland
A16.
Phase I Study of Post Transplant Interleukin-12 Following High Dose
Cyclophosphamide, Thiotepa, and Carboplatin in Women with Metastatic
Breast Carcinoma
Protocol
IDs: BIH-L97-0252, NCI-T98-0002
David Avigan,
Principal Investigator
Ph: 617-667-9920 Beth Israel Deaconess Medical Center Boston, Massachusetts
A17.
Phase I Study of R115777 and Trastuzumab (Herceptin) in Patients
with Advanced or Metastatic Adenocarcinoma
Protocol
IDs: UTHSC-IDD-99-26, NCI-62, SACI-IDD-99-26
Anthony W.
Tolcher, Principal Investigator
Ph: 210-616-5914 Institute for Drug Development San Antonio,
Texas
A18.
Phase I Study of Recombinant Vaccinia DF3/MUC1 Vaccine in Patients
with Metastatic Breast Cancer
Protocol
IDs: DFCI-97050, NCI-T98-0057
Donald W.
Kufe, Principal Investigator
Ph: 617-632-3141 Brigham and Women's Hospital Dana-Farber
Cancer Institute Boston, Massachusetts
A19.
Phase I Study of SU5416 and Doxorubicin in Patients With Stage IIIB
or IV Inflammatory Breast Cancer
Protocol
IDs: CWRU-5199, NCI-T99-0099
Beth A. Overmoyer,
Principal Investigator
Ph: 216-844-5176 Ireland Cancer Center Cleveland, Ohio
A20.
Phase I Study of the Etanidazole Derivative EF5 for the Detection
of Hypoxia in Patients with Breast, Prostate, or Cervical Carcinoma
or High Grade Soft Tissue Sarcomas
Protocol
IDs: CAN-OCI-T98-0048, NCI-T98-0048
Anthony Fyles,
Principal Investigator
Ph: 416-946-2123 Princess Margaret Hospital Toronto, Ontario,
Canada
A21.
Phase I Study of Yttrium Y 90 Monoclonal Antibody B3 Followed By
Autologous Peripheral Blood Stem Cell Transplantation in Patients
With Relapsed or Metastatic Breast Cancer
Protocol
IDs: NCI-00-C-0206, NCI-213
Michael Bishop,
Chair
Ph: 301-435-2764 Division of Clinical Sciences
A22.
Phase I Study of Yttrium Y 90 Monoclonal Antibody BrE-3 and Indium
In 111 Monoclonal Antibody BrE-3 Followed by Autologous Bone Marrow
or Peripheral Blood Stem Cell Transplantation in Patients with Metastatic
Breast Cancer
Protocol
IDs: CRICC-BB-IND-7186, NCI-V00-1637, UCHSC-97467
Jerry A.
Peterson, Principal Investigator
Ph: 415-431-3330 Cancer Research Institute of Contra Costa
San Francisco, California
A23.
Phase I Study of Yttrium Y 90-SMT 487 in Patients with Refractory
or Recurrent Somatostatin Receptor Positive Malignant Neoplasms
Protocol
IDs: MCC-12275, NCI-G00-1857, MCC-IRB-5473, NOVARTIS-SMT-B151
Larry K.
Kvols, Principal Investigator
Ph: 813-972-8400, ext. 8286 H. Lee Moffitt Cancer Center and
Research Institute Tampa, Florida
A24.
Phase I Vaccine Study of HER-2/neu Peptides Incorporated into Polyactide-co-glycolide
(PLG) Microspheres in Patients with Advanced Stage HER-2/neu Expressing
Cancers
Protocol IDs: UWASH-103, NCI-V99-1574
Mary L. (Nora)
Disis, Principal Investigator
Ph: 206-616-1823 University of Washington School of Medicine
Seattle, Washington
A25.
Phase I/II Pilot Study of Stem Cell Mobilization With Paclitaxel
and Cyclophosphamide Followed By High Dose Melphalan and Etoposide
With Autologous Peripheral Blood Stem Cell Rescue in Patients with
Metastatic or High Risk Breast Cancer
Protocol
IDs: NCI-96-C-0104G, NCI-T95-0078N
Ronald E.
Gress, Principal Investigator
Ph: 301-435-4654 Medicine Branch Bethesda, Maryland
A26.
Phase I/II Randomized Study of Ex Vivo Expanded Megakaryocytes in
Women with Stage IIIB or IV Breast Cancer
Protocol
IDs: NU-97B2. NCI-V00-1611
Jane N. Winter,
Principal Investigator
Ph: 312-695-6180 Robert H. Lurie Comprehensive Cancer Center
Northwestern University Chicago, Illinois
A27.
Phase I/II Study of Active Immunotherapy with Carcinoembryonic Antigen
(CEA) RNA Pulsed Autologous Dendritic Cells in Patients with Metastatic
Breast Cancer Who Achieve a Complete Response after High Dose Chemotherapy
and Stem Cell Support
Protocol
IDs: DUMC-97148, NCI-G98-1455
Herbert Kim
Lyerly, Principal Investigator
Ph: 919-681-8350 Duke Comprehensive Cancer Center
Durham, North Carolina
A28.
Phase I/II Study of Capecitabine and Vinorelbine in Elderly Women
with Metastatic Breast Cancer With or Without Bone Involvement
Protocol
IDs: SWS-SAKK-25/99, EU-99007
D. Hess,
Principal Investigator
Ph: 071-494-11-11 Kantonsspital - Saint Gallen Saint Gallen,
Switzerland
A29.
Phase I/II Study of Capecitabine, Paclitaxel, and Trastuzumab (Herceptin)
in Patients With Metastatic Breast Cancer
Protocol
IDs: UNC-9904, NCI-G00-1834
Frances A.
Collichio, Principal Investigator
Ph: 919-966-4431 Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
A30.
Phase I/II Study of Docetaxel and Flavopiridol in Patients with
Previously Treated Locally Advanced or Metastatic Adenocarcinoma
of the Breast
Protocol
IDs: NCI-00-C-0212, NCI-952
Sandra M.
Swain, Principal Investigator
Ph: 301-496-4916 Medicine
Branch Bethesda, Maryland
A31.
Phase I/II Study of Docetaxel/Epirubicin with and without G-CSF
as First-Line Therapy for Metastatic Breast Cancer
Protocol
IDs: CAN-NCIC-MA15, NCI-V96-1063
Maureen E.
Trudeau, Principal Investigator
Ph: 416-480-5145 Women's College Campus, Sunnybrook and Women's
College Health Science Center Toronto, Ontario, Canada
A32.
Phase I/II Study of Doxorubicin HCL Liposome and Trastuzumab (Herceptin)
in Women with Locally Advanced, Inflammatory, or Metastatic Breast
Cancer
Protocol
IDs: MSKCC-99054, NCI-G00-1684, LIPO-D9905
Clifford
A. Hudis, Principal Investigator
Ph: 212-639-6483 Memorial Sloan-Kettering Cancer Center New
York, New York
A33.
Phase I/II Study of Doxorubicin HCl Liposome and Trastuzumab (Herceptin)
in Women with Advanced HER-2/Neu-Overexpressing Breast Cancer
Protocol
IDs: NYU-0012, NCI-G00-1878, ALZA-00-001-ii
Franco M.
Muggia, Principal Investigator
Ph: 212-263-6485 NYU School of Medicine's Kaplan Comprehensive
Cancer Center New York, New York
A34.
Phase I/II Study of High Dose Radioimmunotherapy With Yttrium Y
90 Anti-CEA Monoclonal Antibody MN-14 Plus Peripheral Blood Stem
Cell Rescue in Patients with Stage IV Breast Cancer
Protocol
IDs: CMMI-C-041A-98, NCI-H99-0039, NCI-V99-1568
Jack D. Burton,
Principal Investigator
Ph: 973-844-7024 Garden State Cancer Center Belleville, New
Jersey
A35.
Phase I/II Study of Infusion of Activated T Cells and Low Dose Interleukin-2
Combined with
Autologous Peripheral Blood Stem Cell Transplantation in Women With
Stage IIIB or Metastatic Adenocarcinoma of the Breast
Protocol
IDs: STLMC-BRM-9503, NCI-V96-0902
John P. Hanson,
Jr., Principal Investigator
Ph: 414-385-3086 St. Luke's Medical Center Milwaukee, Wisconsin
A36.
Phase I/II Study of Samarium 153 and Autologous Bone Marrow Transplantation
for Stage IV Breast Cancer
Protocol
IDs: LSU-97447, NCI-V97-1341
Benjamin
Barry Weinberger, Principal Investigator
Ph: 318-675-5972 Louisiana State University School of Medicine
Shreveport, Louisiana
A37.
Phase I/II Study of Trastuzumab (Herceptin) Following High Dose
Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation
in Patients with Metastatic Breast Cancer
Protocol
IDs: BIH-99-12, NCI-V00-1610, BIH-W-99-0053-FB
David Avigan,
Principal Investigator
Ph: 617-667-9920 Beth Israel Deaconess Medical Center Boston,
Massachusetts
A38.
1hase II Study of Gemcitabine in Women with Metastatic Breast Cancer
Previously Treated with Doxorubicin and Paclitaxel
Protocol
IDs: MSKCC-98030, NCI-G98-1474
Violante
E. Currie, Principal Investigator
Ph: 212-639-6991 Memorial
Sloan-Kettering Cancer Center New York, New York
A39.
Phase II Pilot Study Comparing Doxorubicin (Adriamycin) and Paclitaxel
(Taxol) Induced Locally Advanced Breast Cancer
Protocol
IDs: GUMC-97018, NCI-V97-1276
Daniel F.
Hayes, Principal Investigator,
Ph: 202-687-3013 Vincent T. Lombardi Cancer Research Center
Georgetown University Washington, District of Columbia
A40.
Phase II Pilot Study of Adjuvant Paclitaxel, Cyclophosphamide, Filgrastim
(G-CSF), and Doxorubicin Followed by Radiotherapy in Patients with
Stage II or IIIA Breast Cancer
Protocol
IDs: CWRU-1100, NCI-G00-1877, CWRU-050023
Brenda W.
Cooper, Principal Investigator
Ph: 216-844-3213 Ireland Cancer Center Cleveland, Ohio
A41.
Phase II Pilot Study of Allogeneic Peripheral Blood Stem Cell Transplantation
Using Mini-Conditioning Comprised of Fludarabine and Cyclophosphamide,
Followed By Donor Lymphocyte Infusion in Women with Stage IV Breast
Cancer
Protocol
IDs: CWRU-1199, NCI-G00-1855
Hillard M.
Lazarus, Principal Investigator
Ph: 216-844-3629 Ireland Cancer Center Cleveland, Ohio
A42.
Phase II Pilot Study of High Dose Doxorubicin, Cyclophosphamide,
Paclitaxel, and Amifostine Followed By Peripheral Stem Cell Rescue
in Patients with High Risk Stage II/III and Responsive Stage IV
Advanced Breast Cancer
Protocol
IDs: CHNMC-IRB-99002, NCI-G99-1527, ALZA-CHNMC-IRB-99002
George Somlo,
Principal Investigator
Ph: 626-359-8111 Beckman Research Institute, City of Hope Los
Angeles, California
A43.
Phase II Pilot Study of PSC 833 Modulation of Paclitaxel for Recurrent
or Metastatic Breast Cancer
Protocol
IDs: E-1195
Robert W.
Carlson, Chair
Ph: 650-723-7621 Eastern Cooperative Oncology Group
A44.
Phase II Pilot Study of Trastuzumab (Herceptin) Plus Docetaxel in
Women with HER2-Neu Overexpressing Recurrent or Metastatic Breast
Cancer
Protocol
IDs: VU-VCC-BRE-9823, NCI-G00-1830
Brenda P.
Nicholson, Principal Investigator
Ph: 615-322-4967 Vanderbilt Cancer Center Nashville, Tennessee
A45.
Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines with
or without Cellular Immunotherapy with Peptide-Activated Lymphocytes
plus Interleukin-2
Protocol
IDs: NCI-95-C-0105A, NCI-T94-0096N
Samir N.
Khleif, Principal Investigator
Ph: 301-496-0901 Medicine Branch Bethesda, Maryland
A46.
Phase II Randomized Study of Amifostine in Patients with Hematologic
Malignancies and Solid Tumors Receiving Cyclophosphamide, Etoposide,
and Cisplatin Chemotherapy
Protocol
IDs: SCRF-98014, NCI-V98-1396, ALZA-97-49-ii
James Ronald
Mason, Principal Investigator
Ph: 858-554-8597 Scripps Clinic La Jolla, California
A47.
Phase II Randomized Study of Bexarotene (LGD1069) in Patients with
Advanced Breast Cancer
Protocol
IDs: LIGAND-L1069-34, MSKCC-99008 UMN-9808M00110
George Daniel
Demetri, Principal Investigator
Ph: 617-632-3985 Dana-Farber Cancer Institute Boston, Massachusetts
A48.
Phase II Randomized Study of Doxorubicin, Cyclophosphamide, and
Paclitaxel (ACT) vs Cyclophosphamide, Thiotepa, and Carboplatin
(STAMP V) in Patients with High Risk Primary Breast Cancer
Protocol
IDs: CHNMC-IRB-98096, NCI-H99-0038, CHNMC-PHII-18
George Somlo,
Principal Investigator
Ph: 626-359-8111 Beckman Research Institute, City of Hope Los
Angeles, California
A49.
Phase II Randomized Study of ERA-923 in Postmenopausal Women with
Metastatic Breast Cancer Refractory to Tamoxifen
Protocol
IDs: MCC-12235, NCI-G00-1871, GENE-C9944-33, MCC-IRB-5757,
W-AR-3077A1-200-US
Susan Minton,
Principal Investigator
Ph: 813-972-4673 H.
Lee Moffitt Cancer Center and Research Institute Tampa, Florida
A50.
Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal
Women with a History of Stage I, II, or III Breast Cancer Who Have
No Clinical Evidence of Disease
Protocol
IDs: MSKCC-99017, NCI-G99-1662
Clifford
A. Hudis, Principal Investigator
Ph: 212-639-6483 Memorial Sloan-Kettering Cancer Center New
York, New York
A51.
Phase II Randomized Study of Interleukin-12 in Patients with Metastatic
or Recurrent Breast Cancer
Protocol IDs: CLB-49806
Daniel F.
Hayes, Principal Investigator
Ph: 202-687-3013 Vincent T. Lombardi Cancer Research Cente,
Georgetown University Washington, District of Columbia
A52.
Phase II Randomized Study of Irinotecan for Refractory Metastatic
Breast Cancer
Protocol
IDs: NCCTG-963255
Edith A.
Perez, Principal Investigator
Ph: 904-953-7283 Mayo Clinic Cancer Center Rochester, Minnesota
A53.
Phase II Randomized Study of Methotrexate with or without Antineoplaston
A10 Capsules in Women with Advanced Breast Cancer
Protocol
IDs: BRI-BR-10
Stanislaw
R. Burzynski, Principal Investigator
Ph: 713-335-5697 Burzynski Research Institute Houston, Texas
A54.
Phase II Randomized Study of Paclitaxel, Carboplatin, and Trastuzumab
(Herceptin) as First-Line Chemotherapy in Women with Overexpressed
HER-2, Metastatic Breast Cancer
Protocol
IDs: NCCTG-983252
Edith A.
Perez, Principal Investigator
Ph: 904-953-7283 Mayo Clinic Cancer Center Rochester, Minnesota
A55.
Phase II Randomized Study of Subcutaneous Trastuzumab (Herceptin)
Plus Paclitaxel in Women with HER2 Overexpressing Metastatic Breast
Cancer
Protocol
IDs: MSKCC-99118, NCI-G00-1769, GEN-H1994g
Andrew D.
Seidman, Principal Investigator
Ph: 212-636-5875 Memorial Sloan-Kettering Cancer Center New
York, New York
A56.
Phase II Randomized Study of Two Different Dose Schedules of Doxorubicin
HCl Liposome in Women with Metastatic Breast Cancer
Protocol
IDs: IDBBC-10993
Robert E.
Coleman, Principal Investigator
Ph: 114 226 5213 Weston Park Hospital Sheffield, England, United
Kingdom
A57.
Phase II Randomized Study of Two Different Schedules of Docetaxel
or Paclitaxel in Women with Unresectable Locally Advanced or Metastatic
Breast Cancer
Protocol
IDs: FRE-GERCOR-TAXMAX-SOO-1, EU-20029, GERCOR
Joseph Gligorov,
Chair
Ph: 1-40-30-6024
A58.
Phase II Randomized Study of Vinorelbine/Epirubicin Versus Vinorelbine/Mitoxantrone
Versus Cyclophosphamide/Doxorubicin as Preoperative Chemotherapy
in Women with Early Stage Breast Cancer
Protocol
IDs:RMNHS-TOPIC2, EU-99037
Ian Edward
Smith, Principal Investigator
Ph: 0181 661 3280 Royal Marsden Hospital Sutton, England, United
Kingdom
A59.
Phase II Study of 6-Hydroxymethylacylfulvene (MGI-114) in Patients
With Metastatic Breast Cancer
Protocol
IDs:UTHSC-IDD-98-23, NCI-T98-0060, SACI-IDD-98-23
Lisa Hammond,
Principal Investigator
Ph: 210-616-5970 University of Texas Health Science Center
at San Antonio San Antonio, Texas
A60.
Phase II Study of Adjuvant Dose Intensive, Sequential Chemotherapy
with Doxorubicin, Paclitaxel, and Cyclophosphamide for Resected
Stage II/III Breast Cancer
Protocol
IDs:YALE-HIC-7374, NCI-V95-0720
Barbara A.
Burtness, Principal Investigator
Ph: 203-785-6007 Yale Comprehensive Cancer Center New Haven,
Connecticut
A61.
Phase II Study of Allogeneic Mixed Chimerism Peripheral Blood Stem
Cell Transplantation Utilizing In Vivo and In Vitro Monoclonal Antibody
CD52 (Campath-1H) in Patients with High Risk Hematologic Malignancies
or Diseases
Protocol
IDs:DUMC-1340-99-7, NCI-G99-1617
David A.
Rizzieri, Principal Investigato,
Ph: 919-668-1040 Duke Comprehensive Cancer Center Durham, North
Carolina
A62.
Phase II Study of Antineoplastons A10 and AS2-1 in Patients with
Stage IV Breast Carcinoma
Protocol
IDs:BRI-BR-12
Stanislaw
R. Burzynski, Principal Investigator
Ph: 713-335-5697 Burzynski Research Institute Houston, Texas
A63.
Phase II Study of Bryostatin 1 for the Treatment of Stage IV Breast
Cancer
Protocol
IDs:UCHSC-97751, NCI-T97-0063
Andrew S.
Kraft, Principal Investigator
Ph: 303-315-8802 University of Colorado Cancer Center Denver,
Colorado
A64.
Phase II Study of Celecoxib and Trastuzumab (Herceptin) in Women
with HER2/neu Overexpressing Metastatic Breast Cancer That Is Refractory
to Prior Trastuzumab
Protocol
IDs: MSKCC-00078, NCI-G00-1869
Clifford
A. Hudis, Principal Investigator
Ph: 212-639-6483 Memorial Sloan-Kettering Cancer Center New
York, New York
A65.
Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin Followed
by Autologous Hematopoietic Stem Cell Transplantation in Women with
Breast Cancer
Protocol
IDs: MCC-11072 NCI-G00-1760 MCC-IRB-3898
Karen K.
Fields, Principal Investigator
Ph: 813-979-7202 H. Lee Moffitt Cancer Center and Research
Institute Tampa, Florida
A66.
Phase II Study of Docetaxel and Carboplatin as First Line Therapy
in Patients with Metastatic Adenocarcinoma of the Breast
Protocol
IDs: NCCTG-N9932
Michael J.
O'Connell, Chair
Ph: 507-284-2511 North Central Cancer Treatment Group
A67.
Phase II Study of Docetaxel Combined with Estramustine in Patients
with Metastatic Breast Cancer
Protocol
IDs: CPMC-IRB-7929 NCI-V97-1325
Amy D. Tiersten,
Principal Investigator
Ph: 212-305-0170 Herbert Irving Comprehensive Cancer Center
New York, New York
A68.
Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as
Primary Therapy in Women with Stage III Breast Cancer
Protocol
IDs: NU-98B1 NCI-G99-1643
William John
Gradishar, Principal Investigator
Ph: 312-695-4541 Robert H. Lurie Comprehensive Cancer Center
Northwestern University Chicago, Illinois
A69.
Phase II Study of Dose Intensive Chemotherapy and Stem Cell Rescue
in Patients with Inflammatory Stage IIIB Breast Cancer
Protocol
IDs: CHNMC-96139 NCI-G97-1288
George Somlo,
Principal Investigator
Ph: 626-359-8111 Beckman Research Institute, City of Hope Los
Angeles, California
A70.
Phase II Study of Doxorubicin HCl Liposome and Docetaxel with or
without Trastuzumab (Herceptin) in Women With Metastatic Breast
Cancer
Protocol
IDs: E-3198
Antonio C.
Wolff, Chair
Ph: 410-614-4192 Eastern Cooperative Oncology Group
A71.
Phase II Study of Doxorubicin-HPMA Conjugate (PK1) in Women with
Advanced Breast Cancer
Protocol
IDs: CRC-PHASE-II-PH2/038, EU-97028
Stanley Bernard
Kaye, Chair,
Ph: 0141-211-2824 Cancer Research Campaign Clinical Trials
Unit Glasgow
A72.
Phase II Study of DX-8951f in Women With Metastatic Adenocarcinoma
of the Breast Who Have Failed Prior Therapy
Protocol
IDs: DAIICHI-8951A-PRT011, MDA-ID-98308
Robert L.
DeJager, Chair
Ph: 201-573-7160 Daiichi Pharmaceutical Corporation
Francisco
J. Esteva, Principal Investigator
Ph: 713-792-2817 University of Texas - MD Anderson Cancer Center
Houston, Texas
A73.
Phase II Study of Etoposide, Ifosfamide, Mesna, and Cisplatin in
Patients with Metastatic Breast Cancer
Protocol IDs: CWRU-4196, NCI-G00-1854, BMS-CRWU-4196
Paula Silverman,
Principal Investigator
Ph: 216-844-8510 Ireland Cancer Center Cleveland, Ohio
A74.
Phase II Study of Fluorouracil-Uracil and Leucovorin Calcium as
First Line Therapy in Women with Metastatic Breast Cancer
Protocol IDs: NU-99B3, NCI-G00-1741, BMS-NU-99B3, NU-DRUG-BMS-ORZEL
Jamie Hayden Von Roenn, Principal Investigator
Ph: 312-695-6180
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois
A75.
Phase II Study of Gemcitabine and Doxorubicin HCl Liposome in Women
with Metastatic Breast Cancer
Protocol
IDs: MDA-DM-97127, NCI-1650
Edgardo Rivera,
Principal Investigator
Ph: 713-792-2817 University of Texas - MD Anderson Cancer Center
Houston, Texas
A76.
Phase II Study of High Dose Combination Chemotherapy and Autologous
or Syngeneic Peripheral Blood Stem Cell Rescue Followed by Immunotherapy
With Interleukin-2 and Sargramostim (GM-CSF) in Patients with Inflammatory
Stage IIIB and Responsive Metastatic Stage IV Breast Cancer
Protocol
IDs: FHCRC-1229.00, NCI-G98-1399, PSOC-1605
Frederick
R. Appelbaum, Principal Investigator
Ph: 206-667-4412 Fred Hutchinson Cancer Research Center Seattle,
Washington
A77.
Phase II Study of High Dose Topotecan With Ifosfamide and Etoposide
Followed by Autologous Peripheral Blood Stem Cell Rescue in Women
with Metastatic Breast Cancer
Protocol
IDs: MCC-12220, NCI-G00-1809, MCC-IRB-5699
Karen K.
Fields, Principal Investigator
Ph: 813-979-7202 H. Lee Moffitt Cancer Center and Research
Institute Tampa, Florida
A78.
Phase II Study of Interleukin-11 With Filgrastim (G-CSF) in the
Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's
Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
Protocol
IDs: FHCRC-1365.00, NCI-G99-1622
Leona Holmberg,
Principal Investigator
Ph: 206-667-6447 Fred Hutchinson Cancer Research Center Seattle,
Washington
A79.
Phase II Study of LY231514 and Gemcitabine in Women with Metastatic
Breast Cancer
Protocol
IDs:NCCTG-983253
Michael J.
O'Connell, Chair
Ph: 507-284-2511 North Central Cancer Treatment Group
A80.
Phase II Study of Neoadjuvant Doxorubicin, Cyclophosphamide, and
Paclitaxel with or without Trastuzumab (Herceptin) Followed by Local
Surgery With or Without Adjuvant Trastuzumab OR Adjuvant Doxorubicin,
Cyclophosphamide, Paclitaxel, and Trastuzumab in Women With Stage
IIB, IIIA, IIIB, or IV Breast Cancer
Protocol
IDs: UNC-9818, NCI-G00-1836
Mark L. Graham,
Principal Investigator
Ph: 919-859-6631 Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
A81.
Phase II Study of Neoadjuvant Sequential Doxorubicin and Docetaxel
in Women with Stage III Breast Cancer
Protocol
IDs: MCC-11971, NCI-G00-1763, MCC-IRB-5292
Susan Minton,
Principal Investigator
Ph: 813-972-4673 H. Lee Moffitt Cancer Center and Research
Institute Tampa, Florida
A82.
Phase II Study of Nitrocamptothecin in Patients with Locally Recurrent
or Metastatic Breast Cancer
Protocol
IDs: SUPERGEN-RFS2000-17 IUMC-9906-11
Show-Li Sun,
Principal Investigator
Ph: 925-327-0200 SuperGen, Incorporated San Ramon, California
A83.
Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem
Cell and Donor Lymphocyte Infusions in Patients with Refractory
Metastatic Solid Tumors
Protocol
IDs: NHLBI-99-H-0064
Richard W.
Childs, Principal Investigator
Ph: 301-496-5093 National Heart, Lung, and Blood Institute
Bethesda, Maryland, U.S.A.
A84.
Phase II Study of Oral Antineoplastons A10 and AS2-1 in Patients
with Advanced Breast Cancer
Protocol
IDs: BRI-BR-14
Stanislaw
R. Burzynski, Principal Investigator
Ph: 713-335-5697 Burzynski Research Institute Houston, Texas
A85. Phase II Study of Oxaliplatin in Women with Advanced or Metastatic
Breast Cancer Following Failure of Anthracycline/Taxane Based Chemotherapy
Protocol
IDs: EORTC-16001
Pierre Fumoleau,
Principal Investigator
Ph: 33-2-40-67-99-00 CRLCC Nantes - Atlantique Nantes-Saint
Herblain, France
A86.
Phase II Study of Paclitaxel and Capecitabine in Patients With Metastatic Breast
Cancer
Protocol
IDs: ROCHE-M66104C
William John
Gradishar, Chair
Ph: 312-695-4541 Roche Laboratories- Division of Hoffmann-La
Roche, Inc. Principal
Investigators
U.S.A. North
Carolina Patient Contact PPD Development Principal Investigator
Ph: 877-215-7851 PPD Development Wilmington, North Carolina
A87.
Phase II Study of Paclitaxel With or without Trastuzumab (Herceptin)
Following High Dose Chemotherapy with Autologous or Syngeneic Peripheral
Blood Stem Cell Transplantation in Patients with Stage IV Breast
Cancer
Protocol
IDs: FHCRC-1338.00, NCI-G99-1557, GEN-FHCRC-1338.00
Leona Holmberg,
Principal Investigator
Ph: 206-667-6447 Fred Hutchinson Cancer Research Center Seattle,
Washington
A88.
Phase II Study of Preoperative High Dose Chemotherapy with Sequential
Doxorubicin and Docetaxel in Women with Stage II-IIIB Breast Cancer
Protocol
IDs: CWRU-2198, NCI-G99-1537
Paula Silverman,
Principal Investigator
Ph: 216-844-8510 Ireland Cancer Center Cleveland, Ohio
A89.
Phase II Study of Pyrazoloacridine in Women with Metastatic Breast
Cancer
Protocol
IDs: OSU-9712, NCI-T96-0120
Eric H. Kraut,
Principal Investigator
Ph: 614-293-3161 Arthur G. James Cancer Hospital - Ohio State
University Columbus, Ohio
A90.
Phase II Study of Raloxifene as a Chemopreventive Agent for Premenopausal
Women at High Risk for Developing Invasive Breast Cancer
Protocol
IDs: NCI-98-C-0123, MB-402
JoAnne Zujewski,
Principal Investigator,
Ph: 301-402-0985 Medicine Branch Bethesda, Maryland
A91.
Phase II Study of Rebeccamycin Analogue in Patients with Stage IIIB
or IV Breast Cancer
Protocol
IDs: DFCI-99283, NCI-197, CWRU-DFCI-1199
Harold J.
Burstein, Principal Investigator
Ph: 617-632-3800 Dana-Farber Cancer Institute Boston, Massachusetts
A92.
Phase II Study of Sequential High-Dose Cyclophosphamide, Melphalan,
and Thiotepa Followed by Peripheral Blood Stem Cell Rescue in Chemotherapy-Sensitive
Metastatic Breast Cancer
Protocol
IDs: YALE-HIC-7372, NCI-V95-0721
Barbara A.
Burtness, Principal Investigator
Ph: 203-785-6007 Yale Comprehensive Cancer Center New Haven,
Connecticut
A93.
Phase II Study of T-Cell Depleted Allogeneic Peripheral Blood Stem
Cell Transplantation in Patients with Metastatic Breast Cancer
Protocol
IDs: NCI-00-C-0119, NCI-1027
Michael Bishop,
Principal Investigator
Ph: 301-435-2764 Medicine Branch Bethesda, Maryland
A94.
Phase II Study of Tamoxifen and Tretinoin in Women With Stage IV
or Recurrent Breast Cancer Resistant to Tamoxifen
Protocol
IDs: SWOG-S9919
Charles A.
Coltman, Jr., Chair
Ph: 210-616-5580 Southwest Oncology Group
A95.
Phase II Study of the Predictive Value of the Extreme Drug Resistance
Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer
Protocol
IDs: ONCOTECH-OTBR01, NCI-V98-1391, UCIRVINE-97-02
Rita S. Mehta,
Chair
Ph: 714-798-5933 Oncotech, Inc. John Butler
Principal
Investigator
Ph: 714-456-8030 Chao Family Comprehensive Cancer Center Orange,
California
A96.
Phase II Study of Topical Ceramide Cream in Women with Cutaneous
Breast Cancer
Protocol
IDs: NCCTG-N0031
Michael J.
O'Connell, Chair
Ph: 507-284-2511 North Central Cancer Treatment Group
A97.
Phase II Study of Trastuzumab (Herceptin) and Paclitaxel in Patients
With HER2 Overexpressing Breast or Ovarian Tumors Who Have Relapsed
or Progressive Disease Following Chemotherapy for Metastatic Disease
Protocol
IDs: NCI-99-C-0121, NCI-T98-0087
Susan Elaine
Bates, Principal Investigator
Ph: 301-402-1357 Medicine Branch Bethesda, Maryland
A98.
Phase II Study of Trastuzumab (Herceptin) and Radiotherapy in Women
with Stage III or IV Invasive Primary Carcinoma of the Breast That
Continues to Overexpress HER2 Following Neoadjuvant Chemotherapy
Protocol
IDs: UNC-9925, NCI-G00-1835
Carolyn Sartor,
Principal Investigator
Ph: 919-966-7700 Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
A99.
Phase II Study of Vaccination with Glycosylated MUC-1 Antigen with
Keyhole Limpet Hemocyanin Conjugate Plus Immunological Adjuvant
QS21 in Patients with High Risk Breast Cancer
Protocol
IDs: MSKCC-99023, NCI-H99-0043
Teresa Ann
Gilewski, Principal Investigator
Ph: 212-639-8319 Memorial Sloan-Kettering Cancer Center New
York, New York
A100.
Phase II Study of Vinorelbine and Docetaxel in Women with Metastatic
Breast Cancer
Protocol
IDs: WHC-2000056, NCI-V00-1631
David J.
Perry, Principal Investigator
Ph: 202-877-2843 Washington Cancer Institute Washington, District
of Columbia
A101.
Phase III Multicenter, Randomized, Controlled Study of THERATOPE
Vaccine for Metastatic Breast Cancer
Protocol
IDs: BIOMIRA-STn-BR-104, NCI-V98-1489
Participating
Organizations/Investigators BIOMIRA Customer Service (North America),
Chair
Ph: 1-877-234-0444 ext. 500
BIOMIRA INC.Principal
Investigators Canada BIOMIRA Customer Service (North America), Principal
Investigator
Ph: 1-877-234-0444 ext. 500
BIOMIRA INC. Edmonton, Alberta, Canada
A102.
Phase III Postsurgical Maintenance Immunotherapy with Corynebacterium
granulosum P40 for Patients with Colon and Breast Cancer and Melanoma
Residual Following Surgery
Protocol
IDs: ARG-CO/BR-1
Hugo Omar
De Carli, Principal Investigator
Ph: 021-84-3119 Centro Oncologico de Excelencia Gonnet, Buenos
Aires, Argentina
A103.
Phase III Randomized Comparison of Cyclophosphamide/Methotrexate/Fluorouracil
(CMF) Versus Sequential Epirubicin Followed by CMF as Adjuvant Chemotherapy
for Women with Early Stage Breast Cancer
Protocol
IDs: SCTN-BR9601, EU-97013
Chris Twe
lves, Chair
Ph: 0141-211-1712 Scottish Cancer Therapy Network
A104.
Phase III Randomized Comparison of High Dose Chemotherapy Plus Filgrastim
to Filgrastim for Mobilization of Peripheral Blood Stem Cells for
Autologous Transplantation for Patients with Responsive Metastatic
Breast Cancer or High Risk Stage II and III Patients
Protocol
IDs: MDA-DM-95047, NCI-G96-1014
James Gajewski,
Principal Investigator
Ph: 713-745-1644 University of Texas - MD Anderson Cancer Center
Houston, Texas
A105.
Phase III Randomized Study of Adjuvant Chemotherapy with Epirubicin
Plus Paclitaxel Versus Cyclophosphamide, Epirubicin, and Fluorouracil
in Women with Stage IIA, IIB, or III Breast Cancer
Protocol
IDs: INRC-GONO-MIG-5, NCI-V99-1562
Riccardo
Rosso, Principal Investigator
Ph: 0039-010-5600-6686 Istituto
Nazionale per la Ricerca sul Cancro Genoa (Genova), Italy
A106.
Phase III Randomized Study of Adjuvant Cyclophosphamide, Methotrexate,
and Fluorouracil with or without Epirubicin in Women with Early
Stage Breast Cancer
Protocol
IDs: CRC-TU-NEAT, EU-98041
Helena Earl,
Principal Investigator
Ph: 01223-274312 Addenbrooke's NHS Trust Cambridge, England,
United Kingdom
A107.
Phase III Randomized Study of Adjuvant Docetaxel and Doxorubicin
Versus Doxorubicin with or without Cyclophosphamide, Followed By
Combination Chemotherapy in Women With Node Positive Breast Cancer
Protocol
IDs: BIG-2-98, EU-20002, RP-56976-V-315
Martine J.
Piccart-Gebhart, Principal Investigator
Ph: 32-2-5413206 Institut Jules Bordet Brussels (Bruxelles),
Belgium
A108.
Phase III Randomized Study of Adjuvant Letrozole Versus Tamoxifen
in Postmenopausal Women With Operable, Hormone Receptor Positive
Breast Cancer
Protocol
IDs: IBCSG-1-98, EU-99022, IBCSG-18-98 NOVARTIS-2026703019
Henning T.
Mouridsen, Principal Investigator
Ph: 35454776 Rigshospitalet Copenhagen, Denmark
A109.
Phase III Randomized Study of Adjuvant Tamoxifen plus Cyclophosphamide/Methotrexate/Fluorouracil
(CMF) vs Tamoxifen Alone in Postmenopausal Women with Operable,
Invasive Breast Cancer
Protocol
IDs: EU-94003, UKCCCR-ABC/BR9402
W.D. George,
Chair, Principal Investigator
Ph: 0141-211-2166 University of Glasgow Scottish Cancer
Therapy Network Glasgow, Scotland, United KingdomSCTN-BR9402
A110.
Phase III Randomized Study of Adjuvant Tamoxifen with or without
Ovarian Suppression and/or Cyclophosphamide/Methotrexate/Fluorouracil
(CMF) in Premenopausal Women with Operable Invasive Breast Cancer
Protocol
IDs: SCTN-BR9401, EU-94002, UKCCCR-ABC/BR9401
W.D. George,
Chair, Principal Investigator
Ph: 0141-211-2166 University of Glasgow Scottish Cancer
Therapy Network Glasgow, Scotland, United Kingdom
A111.
Phase III Randomized Study of Adjuvant Tamoxifen, Ovarian Suppression,
and/or Chemotherapy in Women with Stage I, II, and IIIA Breast Cancer
Protocol
IDs: UKCCCR-ABC, EU-94029
John Robert
Yarnold, Principal Investigator
Ph: 020 8661 3891 Royal Marsden Hospital Sutton, England, United
Kingdom
A112.
Phase III Randomized Study of Caspofungin Acetate Versus Amphotericin
B Liposomal in Patients with Persistent Fever and Neutropenia Following
Treatment for Cancer
Protocol
IDs: MSKCC-00085, NCI-G00-1898, MERCK-026-01
Kent Sepkowitz,
Principal Investigator
Ph: 212-639-2375 Memorial Sloan-Kettering Cancer Center New
York, New York
A113.
Phase III Randomized Study of Chemotherapy and Surgery Comparing
Adjuvant Doxorubicin Followed By CMF (Cyclophosphamide, Methotrexate,
and Fluorouracil) vs Adjuvant Doxorubicin and Paclitaxel Followed
By CMF vs Primary Doxorubicin and Paclitaxel Followed By CMF in
Women with Operable Breast Cancer and Tumor Greater Than 2 Centimeters
Protocol
IDs:INT-23/96, EU-97001
Gianni Bonadonna,
Principal Investigator
Ph: 2-2390352 Istituto Nazionale per lo Studio e la Cura dei
Tumori Milano (Milan), Italy
A114.
Phase III Randomized Study of Conventional Versus High Dose Chemotherapy
in Women with Node Positive Breast Cancer at Surgery Following Preoperative
Primary Chemotherapy
Protocol
IDs:SCTN-BR9810, EU-98054
T.R.J. Evans,
Principal Investigator
Ph: 0141-330-4171 C.R.C. Beatson Laboratories Glasgow, Scotland,
United Kingdom
A115.
Phase III Randomized Study of Docetaxel in Patients With Metastatic
Breast Cancer
Protocol
IDs:MDA-ID-99242, NCI-1691, AVENTIS-MDA-ID-99242
Edgardo Rivera,
Chair
Ph: 713-792-2817 University of Texas - MD Anderson Cancer Center
A116.
Phase III Randomized Study of Docetaxel vs Paclitaxel in Women with
Advanced Breast Cancer
Protocol
IDs:AVENTIS-56976-TAX-311, NCI-V95-0680, RP-56976-TAX-311
Peter Marcus
Ravdin, Chair, Principal Investigator
Ph: 210-567-4777 University of Texas Health Science Center
at San Antonio San Antonio, Texas, U.S.A. Aventis Pharmaceuticals,
Inc.
A117.
Phase III Randomized Study of Doxorubicin in Combination with Either
Docetaxel or Cyclophosphamide in Women with Potentially Operable,
Locally Advanced or Inflammatory Breast Cancer
Protocol
IDs:SCTN-BR9809, EU-98053
T.R.J. Evans,
Principal Investigator
Ph: 0141-330-4171 C.R.C. Beatson Laboratories Glasgow, Scotland,
United Kingdom
A118.
Phase III Randomized Study of Exemestane Versus Tamoxifen in Postmenopausal
Women with Primary Breast Cancer Who Have Already Received 2-3 Years
of Adjuvant Tamoxifen after Potentially Curable Surgery
Protocol
IDs:ICCG-96OEXE031-C1396-BIG9702, EU-20013, EU-99002,
ICCG-BIG-97/02
Raoul C.
Coombes, Principal Investigator
Ph: 171 8 46 14 18 Charing Cross Hospital London, England,
United Kingdom
A119.
Phase III Randomized Study of High Dose Busulfan, Melphalan, and
Thiotepa Versus Cyclophosphamide, Thiotepa, and Carboplatin Followed
By Autologous Peripheral Blood Stem Cell Transplantation in Patients
with Node Positive Stage II or IIIA Breast Cancer
Protocol
IDs: FHCRC-1316.00, NCI-G99-1552, PSOC-1604
William I.
Bensinger, Principal Investigator
Ph: 206-667-4933 Fred Hutchinson Cancer Research Center Seattle,
Washington
A120.
Phase III Randomized Study of High-Dose Cyclophosphamide, Thiotepa,
and Carboplatin and Autologous Bone Marrow or Peripheral Blood Stem
Cell Transplantation in Conjunction with Cyclosporine and Interferon
Gamma Versus Interleukin-2 as Immunomodulation in Women with High-Risk
Stage II or III Breast Cancer
Protocol
IDs: CPMC-IRB-7608, NCI-G00-1890, CPMC-CAMP-014
Charles S.
Hesdorffer, Principal Investigato,
Ph: 212-305-4907 Herbert
Irving Comprehensive Cancer Center New York, New York
A121.
Phase III Randomized Study of Intensification with Cyclophosphamide/Thiotepa
(CHUT) with Autologous PBSC Support vs No Intensification in Locally
Recurrent or Metastatic Breast Cancer Responsive to Induction with
Epirubicin/Fluorouracil/Cyclophosphamide (FEC 100)
Protocol
IDs: FRE-FNCLCC-PEGASE03, EU-96032
Pierre Biron,
Chair
Ph: 334-78-78-26-41 Federation Nationale des Centres de Lutte
Contre le Cancer
A122.
Phase III Randomized Study of Marimastat versus Placebo in Patients
with Metastatic Breast Cancer Who Have Responding or Stable Disease
after Induction Chemotherapy
Protocol
IDs: E-2196
Joseph A.
Sparano, Chair
Ph: 718-904-2555 Eastern Cooperative Oncology Group
James N.
Ingle, Chair
Ph: 507-284-8432 North Central Cancer Treatment Group
A123.
Phase III Randomized Study of Mitoxantrone with or wWithout Docetaxel
as First-Line Chemotherapy for Women with Poor Risk Metastatic Breast
Cancer
Protocol
IDs: GER-AIO-01/92, EU-93011
Else G. Heidemann,
Principal Investigator,
Ph: 0711-991-3501 Diakonissen Hospital Stuttgart, Germany
A124.
Phase III Randomized Study of Paclitaxel Via One-Hour Infusion Every
Week vs Three-Hour Infusion Every 3 Weeks with or without Trastuzumab
(Herceptin) in Patients with Inoperable, Recurrent, or Metastatic
Breast Cancer with or without Overexpression of HER2-Neu
Protocol
IDs: CLB-9840
Andrew D.
Seidman, Chair
Ph: 212-636-5875 Cancer and Leukemia Group B
A125.
Phase III Randomized Study of Paclitaxel with or without Gemcitabine
in Women with Unresectable, Locally Recurrent, or Metastatic Breast
Cancer
Protocol
IDs: LILLY-B9E-MC-JHQG
Furhan Yunus,
Chair
Ph: 901-725-1785 Eli Lilly and Company
John M. Waples,
Principal Investigator
Ph: 256-551-6546 Comprehensive Cancer Institute of Huntsville
Huntsville, Alabama
A126.
Phase III Randomized Study of Preoperative Doxorubicin and Cyclophosphamide
(AC) Versus Preoperative AC Followed by Docetaxel Versus Preoperative
AC and Postoperative Docetaxel in Women with Operable Carcinoma
of the Breast
Protocol
IDs: NSABP-B-27
Harry D.
Bear, Chair
Ph: 804-828-9325 National Surgical Adjuvant Breast and Bowel
Project
A127.
Phase III Randomized Trial of High Dose Chemotherapy and Autologous
Stem Cell Therapy vs Standard Therapy in Women with Metastatic Breast
Cancer Who Have Responded to Anthracycline or Taxane Based Induction
Chemotherapy
Protocol
IDs: NCIC-Clinical Trials Group, CAN-NCIC-MA16, CNR-9502,
EU-95020, E-1199
Michael Crump,
Chair, Principal Investigator
Ph: 416-946-4567 Toronto General Hospital Toronto, Ontario,
Canada
A128.
Phase III Study of Doxorubicin and Cyclophosphamide Followed By
Paclitaxel or Docetaxel in Women with Node Positive or High Risk
Node Negative Stage II or IIIA Breast Cancer
Joseph A.
Sparano, Chair
Ph: 718-904-2555 Eastern Cooperative Oncology Group
A129.
Companion Study to Evaluate Late Cardiac Effects in Women with Node-Negative
Breast Cancer Receiving Adjuvant Chemotherapy on Protocol SWOG-8897
Protocol
IDs: SWOG-9342
Patricia
A. Ganz, Chai
Ph: 310-206-1404 Southwest Oncology Group
A130.
Genetic Mapping of Interactive Susceptibility Loci in Patients and
Siblings with Breast, Colon, Lung, or Prostate Cancer
Protocol
IDs: E-1Y97
Theodore
G. Krontiris, Principal Investigator
Ph: 626-359-8111 Beckman Research Institute, City of Hope Los
Angeles, California
A131.
Genetic, Clinical, and Epidemiological Study of Individuals and
Families at High Risk of Cancer
Protocol
IDs: NCI-78-C-0039
Margaret
A. Tucker, Principal Investigator
Ph: 301-496-4375 Genetic Epidemiology Branch Bethesda, Maryland
A132.
Pilot Study to Evaluate the Incidence of Clonal Hematopoiesis as
a Marker of Genetic Damage Following Adjuvant Chemotherapy for Stage
II/III Breast Cancer
Protocol
IDs: SWOG-S9719
Marilyn L. Slovak,
Chair
Ph: 818-359-8111x2348 Southwest Oncology Group
A133.
Randomized Pilot Study to Evaluate Educational Intervention and
Behavioral Skills Training for Pain Control in Patients with Recurrent
or Metastatic Breast or Prostate Cancer
Protocol
IDs: E-3Z93, NCI-P95-0068
Charles Cleeland,
Chair
Ph: 713-745-3470 Eastern Cooperative Oncology Group
A134.
Randomized Study of Conventional Care with or without Cancer Care
Intervention in Patients with Breast, Ovarian, Pancreatic, Endometrial,
Colon, or Lung Cancer or Non-Hodgkin's Lymphoma Who Are Receiving
Chemotherapy As Primary Treatment
Protocol
IDs: NCI-P00-0166, MSU-1386005984A1, MSU-9906, MSU-IRB-96479
Barbara A.
Given, Principal Investigator
Ph: 517-353-4920 Michigan State University East Lansing, Michigan
A135.
Randomized Study of Vinorelbine Combined with Chronomodulated Fluorouracil
in Previously Treated Women with Metastatic Breast Cancer
Protocol
IDs: EORTC-05971
Bruno Coudert,
Principal Investigator
Ph: 03-80-73-75-28 Centre de Lute Contre le Cancer,Georges-Francois
Leclerc Dijon, France EORTC Chronotherapy Group
A136.
Randomized Study to Evaluate the Efficacy of Brief Physician-Initiated
Quit-Smoking Strategies for Clinical Oncology Settings
Protocol
IDs: NCI-P93-0042, E-1Y92
Neal Richard
Boyd, Jr., Chair
Ph: 215-728-6900 Eastern Cooperative Oncology Group
A137.
Screening and Diagnostic Study of Digital Mammography Versus Screen-Film
Mammography in the Detection of Breast Cancer in Women
Protocol
IDs: ACRIN-6652
Etta Pisano,
Chair
Ph: 919-966-6957 Hancock Memorial Hospital
A138.
Screening and Diagnostic Study of Magnetic Resonance Imaging in
Women With Suspected Breast Cancer
Protocol
IDs: UPCC-ACR-6884
Mitchell
Schnall, Principal Investigator
Ph: 215-662-7238 University of Pennsylvania Cancer Center Philadelphia,
Pennsylvania
A139.
Screening Study Following Local Excision in Selected Patients with
Ductal Carcinoma in Situ (DCIS) of the Breast
Protocol
IDs: E-5194
Lorie L.
Hughes, Chair
Ph: 404-233-4960 Eastern Cooperative Oncology Group
A140.
Study of Stem Cell Augmented, Elutriated Grafts for Prevention of
Graft Versus Host Disease in Patients Undergoing Allogeneic Bone
Marrow Transplantation
Protocol
IDs: JHOC-97021903, NCI-V98-1460, JHOC-J9711
Paul V. O'Donnell,
Principal Investigator
Ph: 410-614-0205 Johns Hopkins Oncology Center Baltimore, Maryland
|
